Catalyst
Slingshot members are tracking this event:
Titan Pharmaceuticals Announces FDA Approval of Probuphine for the Treatment of Opioid Dependence
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
TTNP |
|
|
Additional Information
Buprenorphine is the most commonly prescribed medication for the treatment of opioid dependence. Until today, it has only been available in daily dosed sublingual (oral) formulations. Probuphine offers the potential to address issues associated with oral buprenorphine such as poor compliance, misuse, diversion and accidental pediatric exposure. Each Probuphine implant contains 80 mg of buprenorphine hydrochloride. Four flexible Probuphine implants, each about the size of a small matchstick, are inserted by a certified healthcare provider just under the skin of the inside of the patient's upper arm through a simple in-office procedure and are removed in a similar manner at the end of treatment.
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 26, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Opioid Dependence, Buprenorphine Implant, Buprenorphine, Proneura